Animal models of melanoma: A somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma

Chinese Journal of Cancer

Volumn 30, Issue 3, 2011, Pages 153-162

  McKinney, Andrea J ^a   Holmen, Sheri L ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

Animal models; Melanoma; RCAS TVA

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHORBOL 13 ACETATE 12 MYRISTATE; RETROVIRUS VECTOR;

CANCER MODEL; CARCINOGENESIS; CARCINOGENICITY; CLINICAL EVALUATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE LOCUS; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; NONHUMAN; ONCOGENE; ONCOGENE RAS; REVIEW; SOMATIC GENE THERAPY; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 79954466827     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10007     Document Type: Review

References (100)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010,60(5):277-300.
2. Seer cancer statistics review, 1975-2007, national cancer institute. SF A, CL K, M K, et al., eds. SEER AYA Monograph. Bethesda, MD, 2007:53-63.
3. Ahmed I. Malignant melanoma: Prognostic indicators [J]. Mayo Clin Proc, 1997,72(4):356-361.
4. Flaherty KT. Narrative review: Braf opens the door for therapeutic advances in melanoma [J]. Ann Intern Med, 2010,153(9):587-591.
5. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, ctivated braf in metastatic melanoma [J]. N Engl J Med, 2010,363(9):809-819.
6. Zaidi MR, Day CP, Merlino G. From uvs to metastases: odeling melanoma initiation and progression in the mouse [J]. J Invest Dermatol, 2008,128(10):2381-2391.
7. Rofstad EK, Lyng H. Xenograft model systems for human elanoma [J]. Mol Med Today, 1996,2(9):394-403.
8. Chudnovsky Y, Adams AE, Robbins PB, et al. Use of human issue to assess the oncogenic activity of melanoma-associated mutations [J]. Nat Genet, 2005,37(7):745-749.
9. Sabzevari H, Reisfeld RA. Human cytotoxic T-cells suppress he growth of spontaneous melanoma metastases in scid/hu ice [J]. Cancer Res, 1993,53(20):4933-4937.
10. Miyata M, Furukawa M, Takahashi K, et al. Mechanism of 7,12-imethylbenz [ajanthracene-induced immunotoxicity: Role of metabolic activation at the target organ [J]. Jpn J Pharmacol, 2001,86(3):302-309.
11. Blumberg PM. Protein kinase c as the receptor for the phorbol stertumor promoters: sixth rhoads memorial award lecture [J]. Cancer Res, 1988,48(1):1-8.
12. Hunter T, Ling N, Cooper JA. Protein kinase c phosphorylation of the egf receptor at a threonine residue close to the cytoplasmic face of the plasma membrane [J]. Nature, 1984,311(5985):480-483.
13. Tormo D, Ferrer A, Gaffal E, et al. Rapid growth of invasive metastatic melanoma in carcinogen-treated hepatocyte growth factor/scatter factor-transgenic mice carrying an oncogenic cdk4 mutation [J]. Am J Pathol, 2006,169(2):665-672.
14. Chawla R, Procknow JA, Tantravahi RV, et al. Cooperativity of cdk4r24c and ras in melanoma development [J]. Cell Cycle, 2010,9(16):3305-3314.
15. Inoue-Narita T, Hamada K, Sasaki T, et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis [J]. Cancer Res, 2008,68(14):5760-5768.
16. Elmets CA, Yusuf N, Hamza S, et al. Topical application of dimethylbenz [ajanthracene results in the generation of multiple melanocytic nevi in c3h/hen mice [J]. Toxicol Appl Pharmacol, 2004,195(3):355-360.
17. Nordlund JJ, Gershon RK. Splenic regulation of the clinical appearance of small tumors [J]. J Immunol, 1975,114(5): 1486-1490.
18. Maguire HC, Jr. Tumor immunology with particular reference to malignant melanoma [J]. Int J Dermatol, 1975,14(1):3-11.
19. Fidler IJ, Darnell JH, Budmen MB. Tumoricidal properties of mouse macrophages activated with mediators from ratlymphocytes stimulated with concanavalin a [J]. Cancer Res, 1976,36(10):3608-3615.
20. Fidler IJ, Nicolson GL. Organ selectivity for implantation survival and growth of b16 melanoma variant tumor lines [J]. J Natl Cancer Inst, 1976,57(5):1199-1202.
21. VanBrocklin MW, Robinson JP, Lastwika KJ, et al. Targeted delivery of nrasq61r and cre-recombinase to post-natal melanocytes induces melanoma in ink4a/arflox/lox mice [J]. Pigment Cell Melanoma Res, 2010,23(4):531-541.
22. Becker JC, Houben R, Schrama D, et al. Mouse models for melanoma: a personal perspective [J]. Exp Dermatol, 2009,19 (2):157-164
23. Sanchez-Perez L, Kottke T, Diaz RM, et al. Potent selection of antigen loss variants of b16 melanoma following inflammatory killing of melanocytes in vivo [J]. Cancer Res, 2005,65(5): 2009-2017.
24. Castellano M, Parmiani G. Genes involved in melanoma: an overview of ink4a and other loci [J]. Melanoma Res, 1999,9(5):421-432.
25. Chin L, Garraway LA, Fisher DE. Malignant melanoma: Genetics and therapeutics in the genomic era [J]. Genes Dev, 2006,20(16):2149-2182.
26. Dankort D, Curley DP, Cartlidge RA, et al. Braf (v600e) cooperates with pten loss to induce metastatic melanoma [J]. Nat Genet, 2009,41 (5):544-552.
27. Milagre C, Dhomen N, Geyer FC, et al. A mouse model of melanoma driven by oncogenic kras [J]. Cancer Res, 2010,70 (13):5549-5557.
28. Monahan KB, Rozenberg GI, Krishnamurthy J, et al. Somatic p16(ink4a) loss accelerates melanomagenesis [J]. Oncogene, 2010,29(43):5809-5817.
29. Nogueira C, Kim KH, Sung H, et al. Cooperative interactions of pten deficiency and ras activation in melanoma metastasis [J]. Oncogene, 2010,29(47):6222-6232.
30. Chin L, Pomerantz J, Polsky D, et al. Cooperative effects of ink4a and ras in melanoma susceptibility in vivo [J]. Genes Dev, 1997,11(21):2822-2834.
31. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead braf and oncogenic ras cooperate to drive tumor progression through craf [J]. Cell, 2010,140(2):209-221.
32. Delmas V, Beermann F, Martinozzi S, et al. Beta-catenin induces immortalization of melanocytes by suppressing p16ink4a expression and cooperates with n-ras in melanoma development [J]. Genes Dev, 2007,21 (22):2923-2935.
33. Ferguson B, Konrad Muller H, Handoko HY, et al. Differential roles of the prb and arf/p53 pathways in murine naevus and melanoma genesis [J]. Pigment Cell Melanoma Res, 2010,23 (6):771-780.
34. Ha L, Ichikawa T, Anver M, et al. Arf functions as a melanoma tumor suppressor by inducing p53-independent senescence [J]. Proc Natl Acad Sci USA, 2007,104(26):10968-10973.
35. Recio JA, Noonan FP, Takayama H, et al. Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis [J]. Cancer Res, 2002,62(22):6724-6730.
36. Held MA, Curley DP, Dankort D, et al. Characterization of melanoma cells capable of propagating tumors from a single cell [J]. Cancer Res, 2010,70(1):388-397.
37. Yang J, Luan J, Yu Y, et al. Induction of melanoma in murine macrophage inflammatory protein 2 transgenic mice heterozygous for inhibitor of kinase/alternate reading frame [J]. Cancer Res, 2001,61(22):8150-8157.
38. Goel VK, Ibrahim N, Jiang G, et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic brafv600e mice [J]. Oncogene, 2009,28(23):2289-2298.
39. Ackermann J, Frutschi M, Kaloulis K, et al. Metastasizing melanoma formation caused by expression of activated n-rasq61k on an ink4a-deficient background [J]. Cancer Res, 2005,65(10):4005-4011.
40. Kato M, Liu W, Akhand AA, et al. Ultraviolet radiation induces both full activation of ret kinase and malignant melanocytic tumor promotion in rfp-ret-transgenic mice [J]. J Invest Dermatol, 2000,115(6):1157-1158.
41. Kumasaka MY, Yajima I, Hossain K, et al. A novel mouse model for de novo melanoma [J]. Cancer Res, 2010,70(1):24-29.
42. von Felbert V, Cordoba F, Weissenberger J, et al. lnterleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma [J]. Am J Pathol, 2005,166(3):831-841.
43. Yang G, Curley D, Bosenberg MW, et al. Loss of xeroderma pigmentosum c (xpc) enhances melanoma photocarcinogenesis in ink4a-arf-deficient mice [J]. Cancer Res, 2007,67(12):5649-5657.
44. Dhomen N, Reis-Filho JS, da Rocha Dias S, et al. Oncogenic braf induces melanocyte senescence and melanoma in mice [J]. Cancer Cell, 2009,15(4):294-303.
45. Hacker E, Irwin N, Muller HK, et al. Neonatal ultraviolet radiation exposure is critical for malignant melanoma induction in pigmented tpras transgenic mice [J]. J Invest Dermatol, 2005,125(5):1074-1077.
46. Hacker E, Muller HK, Irwin N, et al. Spontaneous and uv radiation-induced multiple metastatic melanomas in cdk4r24c/r24c/tpras mice [J]. Cancer Res, 2006,66(6):2946-2952.
47. Sharpless NE, Kannan K, Xu J, et al. Both products of the mouse ink4a/arf locus suppress melanoma formation in vivo [J]. Oncogene, 2003,22(32):5055-5059.
48. Kannan K, Sharpless NE, Xu J, et al. Components of the rb pathway are critical targets of uv mutagenesis in a murine melanoma model [J]. Proc Natl Acad Sci USA, 2003,100(3): 1221-1225.
49. Bardeesy N, Bastian BC, Hezel A, et al. Dual inactivation of rb and p53 pathways in ras-induced melanomas [J]. Mol Cell Biol, 2001,21(6):2144-2153.
50. Pollock PM, Cohen-Solal K, Sood R, et al. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia [J]. Nat Genet, 2003,34(1):108-112.
51. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma [J]. J Clin Oncol, 1998,16(2):670-682.
52. Chin L, Pomerantz J, DePinho RA. The ink4a/arf tumor suppressor: One gene-two products-two pathways [J]. Trends Biochem Sci, 1998,23(8):291-296.
53. Roussel MF. The ink4 family of cell cycle inhibitors in cancer [J]. Oncogene, 1999,18(38):5311-5317.
54. Serrano M, Lee H, Chin L, et al. Role of the ink4a locus in tumor suppression and cell mortality [J]. Cell, 1996,85(1):27-37.
55. Quelle DE, Zindy F, Ashmun RA, et al. Alternative reading frames of the ink4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest [J]. Cell, 1995,83(6):993-1000.
56. Kamijo T, Zindy F, Roussel MF, et al. Tumor suppression at the mouse ink4a locus mediated by the alternative reading frame product p19arf [J]. Cell, 1997,91 (5):649-659.
57. Zhang Y, Xiong Y, Yarbrough WG. Arf promotes mdm2 degradation and stabilizes p53: Arf-ink4a locus deletion impairs both the rb and p53 tumor suppression pathways [J]. Cell, 1998,92(6):725-734.
58. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression [J]. Front Biosci, 1998,3(D):1005-1010.
59. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through map kinase cascades [M]. Vande Woude GF, Klein G, eds. Advances in cancer research. San Diego: Academic Press, 1998:49-139.
60. Barbacid M. Ras oncogenes: their role in neoplasia [J]. Eur J Clin Invest, 1990,20(3):225-235.
61. Davies H, Bignell GR, Cox C, et al. Mutations of the braf gene in human cancer [J]. Nature, 2002,417(6892):949-954.
62. Chin L, Tarn A, Pomerantz J, et al. Essential role for oncogenic ras in tumour maintenance [J]. Nature, 1999,400(6743):468-472.
63. Armstrong BK, Kricker A, English DR. Sun exposure and skin cancer [J]. Australas J Dermatol, 1997,38(Suppl 1):S1-S6.
64. MacKie RM. Incidence, risk factors and prevention of melanoma [J]. Eur J Cancer, 1998,34(Suppl 3):S3-S6.
65. Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies [J]. Cancer Causes Control, 2001,12(1): 69-82.
66. Noonan FP, Recio JA, Takayama H, et al. Neonatal sunburn and melanoma in mice [J]. Nature, 2001,413(6853):271-272.
67. Noonan FP, Otsuka T, Bang S, et al. Accelerated ultraviolet radiation-induced carcinogenesis in hepatocyte growth factor/scatter factor transgenic mice [J]. Cancer Res, 2000,60(14):3738-3743.
68. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis [J]. Cell, 1990,61:759-767.
69. McClatchey Al, Jacks T. Tumor suppressor mutations in mice: The next generation [J]. Curr Opin Genet Dev, 1998,8(3):304-310.
70. Bardeesy N, Wong KK, DePinho RA, et al. Animal models of melanoma: Recent advances and future prospects [J]. Adv Cancer Res, 2000,79:123-156.
71. Furth PA, St Onge L, Boger H, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter [J]. Proc Natl Acad Sci USA, 1994,91(20):9302-9306.
72. Gossen M, Bonin AL, Freundlieb S, et al. Inducible gene expression systems for higher eukaryotic cells [J]. Curr Opin Biotechnol, 1994,5(5):516-520.
73. Shockett P, Difilippantonio M, Hellman N, et al. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice [J].Proc Natl Acad Sci USA, 1995,92(14):6522-6526.
74. Macleod KF, Jacks T. Insights into cancer from transgenic mouse models [J]. J Pathol, 1999,187(1):43-60.
75. Williams BO, Schmitt EM, Remington L, et al. Extensive contribution of rb-deficient cells to adult chimeric mice with limited histopathological consequences [J]. Embo J, 1994,13 (18):4251-4259.
76. Federspiel M, Hughes S. Retroviral gene delivery [M]. Emerson C, Sweeney H, eds. Methods in cell biology: Methods in muscle biology. San Diego: Academic Press, 1997: 179-214.
77. Bates P, Young J, Varmus H. Receptor for subgroup a rous sarcoma virus is related to the low density lipoprotein receptor [J]. Cell, 1993,74:1043-1051.
78. Young J, Bates P, Varmus H. Isolation of a chicken gene that confers susceptibility to infection by subgroup a avian leukosis and sarcoma viruses [J]. Journal of Virology, 1993,67(4):1811-1816.
79. Federspiel MJ, Bates P, Young JA, et al. A system for tissue-specific gene targeting: transgenic mice susceptible to subgroup a avian leukosis virus-based retroviral vectors [J]. Proc Natl Acad Sci USA, 1994,91(23):11241-11245.
80. Holland EC, Hively WP, DePinho RA, et al. A constitutively active epidermal growth factor receptor cooperates with disruption of Gi cell-cycle arrest pathways to induce glioma-like lesions in mice [J]. Genes Dev, 1998,12(23):3675-3685.
81. Murphy GJ, Leavitt AD. A model for studying megakaryocyte development and biology [J]. Proc Natl Acad Sci USA, 1999,96(6):3065-3070.
82. Boerkoel CF, Federspiel MJ, Salter DW, et al. A new defective retroviral vector system based on the bryan strain of rous sarcoma virus [J]. Virology, 1993,195(2):669-679.
83. Himly M, Foster DN, Bottoli I, et al. The df-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses [J]. Virology, 1998,248(2):295-304.
84. Schaefer-Klein J, Givol I, Barsov EV, et al. The ev-o-derived cell line df-1 supports the efficient replication of avian leukosis-sarcoma viruses and vectors [J]. Virology, 1998,248(2):305-311.
85. Sauer B. Inducible gene targeting in mice using the cre/lox system [J]. Methods, 1998,14(4):381-392.
86. Seidler B, Schmidt A, Mayr U, et al. A cre-loxp-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors [J]. Proc Natl Acad Sci USA, 2008,105(29):10137-10142.
87. Fisher GH, Orsulic S, Holland E, et al. Development of a flexible and specific gene delivery system for production of murine tumor models [J]. Oncogene, 1999,18(38):5253-5260.
88. Orsulic S. An rcas-tva-based approach to designer mouse models [J]. Mamm Genome, 2002,13(10):543-547.
89. Dunn KJ, Williams BO, Li Y, et al. Neural crest-directed gene transfer demonstrates wntl role in melanocyte expansion and differentiation during mouse development [J]. Proc Natl Acad Sci USA, 2000,97(18):10050-10055.
90. Dunn KJ, Brady M, Ochsenbauer-Jambor C, et al. Wnt1 and wnt3a promote expansion of melanocytes through distinct modes of action [J]. Pigment Cell Res, 2005,18(3):167-180.
91. Dunn KW, Sandoval RM, Kelly KJ, et al. Functional studies of the kidney of living animals using multicolor two-photon microscopy [J]. Am J Physiol Cell Physiol, 2002,283(3):C905-C916.
92. Steel KP, Davidson DR, Jackson IJ. Trp-2/dct, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor [J]. Development, 1992,115(4): 1111-1119.
93. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering rnas in mammalian cells [J]. Science, 2002,296(5567):550-553.
94. Hemann MT, Fridman JS, Zilfou JT, et al. An epi-allelic series of p53 hypomorphs created by stable rnai produces distinct tumor phenotypes in vivo [J]. Nat Genet, 2003,33(3):396-400.
95. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by rna interference [J]. Nat Genet, 2003,33(3):401-406.
96. Bromberg-White JL, Webb CP, Patacsil VS, et al. Delivery of short hairpin rna sequences by using a replication-competent avian retroviral vector [J]. J Virol, 2004,78(9):4914-4916.
97. Huse JT, Brennan C, Hambardzumyan D, et al. The pten-regulating microrna mir-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo [J]. Genes Dev, 2009,23 (11):1327-1337.
98. Holmen SL, Zylstra CR, Mukherjee A, et al. Essential role of beta-catenin in postnatal bone acquisition [J]. J Biol Chem, 2005,280(22):21162-21168.
99. Kistner A, Gossen M, Zimmermann F, et al. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice [J]. Proc Natl Acad Sci USA, 1996,93(20): 10933-10938.
100. Lewis BC, Chinnasamy N, Morgan RA, et al. Development of an avian leukosis-sarcoma virus subgroup a pseudotyped lentiviral vector [J]. J Virol, 2001,75(19):9339-9344.